Enhanced intelligence community support to secure United States genomic data

(a) In general The Director of National Intelligence, in consultation with such other heads of elements of the intelligence community as the Director considers appropriate, shall provide support to and consult with the Federal Bureau of Investigation, the Committee on Foreign Investment in the United States, and other government agencies as appropriate when reviewing transactions relating to the acquisition of covered entities by foreign entities, including attempts by the Government of the People's Republic of China— (1) to leverage and acquire biological and genomic data in the United States; and (2) to leverage and acquire biological and genomic data outside the United States, including by providing economic support to the military, industrial, agricultural, or healthcare infrastructure of foreign countries of concern. (b) Assessment Not later than 90 days after the date of the enactment of this Act, the Director of National Intelligence shall brief the appropriate congressional committees on— (1) a formal process for ensuring intelligence community support to Federal agencies relating to adversary acquisition of genomic data, in compliance with Executive Order 14117 (50 U.S.C. 1701 note; relating to preventing access to Americans’ bulk sensitive personal data and United States Government-related data by countries of concern), or any successor order; and (2) any additional resources or authorities needed to conduct subsequent intelligence assessments under such subsection. (c) Definitions In this section: (1) Appropriate congressional committees The term appropriate congressional committees means— (A) the congressional intelligence committees; (B) the Committee on Foreign Relations and the Committee on Banking, Housing, and Urban Affairs of the Senate; and (C) the Committee on Foreign Affairs and the Committee on Financial Services of the House of Representatives. (2) Biological data The term biological data means information, including associated descriptors, derived from the structure, function, or process of a biological system, that is either measured, collected, or aggregated for analysis, including information from humans, animals, plants, or microbes. (3) Covered entity The term covered entity means a private entity involved in genomic data (including genomic data equipment, technologies, sequencing, or synthesis), including a biobank or other private entity that holds large amounts of genomic or biological data. (4) Foreign entity of concern The term foreign entity of concern has the meaning given that term in section 10612(a) of the Research and Development, Competition, and Innovation Act (42 U.S.C. 19221(a)).